Related Experiment Video
Updated: Dec 27, 2025

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
Published on: February 19, 2019
Long term follow-up of children with chronic hepatitis B: a single center experience
İnci Yaman Bajin1, Hülya Demir2, İnci Nur Saltık-Temizel2
1Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Insights
Combined treatment with Interferon (IFN) and lamivudine (LMV) showed the highest e-seroconversion rates in children with chronic Hepatitis B. Higher ALT levels correlated with better treatment response in this long-term study.
Area of Science:
- Pediatrics
- Hepatology
- Virology
Background:
- Chronic Hepatitis B infection poses significant risks for cirrhosis and hepatocellular carcinoma.
- Optimal treatment strategies for pediatric chronic Hepatitis B remain debated.
Purpose of the Study:
- To analyze the clinical features and long-term outcomes of children with chronic Hepatitis B.
- To compare the effectiveness of different treatment protocols.
Main Methods:
- Retrospective analysis of 165 children diagnosed with chronic Hepatitis B between 1993 and 2012.
- Patients were categorized into four treatment groups: Interferon (IFN) only, Lamivudine (LMV) then IFN+LMV then LMV, IFN+LMV then LMV, and LMV only.
- Median follow-up period of 7 years (range: 1-19 years).
Main Results:
- Combined IFN+LMV treatment regimens demonstrated the highest rates of e-seroconversion, biochemical, and virological response.
- Patients with elevated ALT levels exhibited a significantly better response to treatment (p: 0.003).
Conclusions:
- Combined Interferon and Lamivudine therapy appears most effective for pediatric chronic Hepatitis B.
- Identifying patients who require treatment is crucial for optimizing therapy and reducing long-term complications like cirrhosis and hepatocellular carcinoma.
Abstract:
Yaman Bajin İ, Demir H, Saltık Temizel İN, Özen H, Yüce A. Long term follow-up of children with chronic hepatitis B: a single center experience. Turk J Pediatr 2019; 61: 846-851. Chronic Hepatitis B infection is an important clinical issue because of the associated risk of developing cirrhosis and hepatocellular carcinoma. Especially in children, there is no consensus about the optimal treatment. Clinical features and long-term outcomes of 165 children diagnosed with chronic hepatitis B at our institution between January 1993 and June 2012 were analysed retrospectively. Patients were divided into four groups according to their treatment protocols. The first group received Interferon (IFN) only, the second group started lamivudine (LMV) first then IFN+LMV combined and then continued with LMV only, the third group started with IFN+LMV combined then continued with LMV only and the fourth group received LMV only. After a median follow-up period of 7 years (1-19 years) the highest e-seroconversion (the loss of HBeAg followed by gain of anti- HBe antibody) rate, biochemical and virological response was observed with combined (IFN+LMV) treatment regimens. Patients with higher ALT levels were better treatment responders (p: 0.003). Identification of the patients who need to be treated in order to determine the most effective therapy with optimal treatment duration is important to reduce the risk of developing future complications like cirrhosis and hepatocellular carcinoma.
More Related Videos
Related Concept Videos
Longitudinal Research
Longitudinal Studies
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

